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Abstract—The p53 tumor suppressor gene plays two important 
roles in genomic stability: blocking cell proliferation after DNA 
damage until it has been repaired, and starting apoptosis if the 
damage is too critical. Codon 72 exon4 polymorphism (Arg72Pro) of 
the P53 gene has been implicated in cancer risk. Various studies have 
been done to investigate the status of p53 at codon 72 for arginine 
(Arg) and proline (Pro) alleles in different populations and also the 
association of this codon 72 polymorphism with various tumors. Our 
objective was to investigate the possible association between P53 
Arg72Pro polymorphism and susceptibility to colorectal cancer 
among Isfahan and Chaharmahal Va Bakhtiari (a part of south west 
of Iran) population. We investigated the status of p53 at codon 72 for 
Arg/Arg, Arg/Pro and  Pro/Pro allele polymorphisms in blood 
samples from 145 colorectal cancer patients and 140 controls by 
Nested-PCR of p53 exon 4 and digestion with BstUI restriction 
enzyme and the DNA fragments were then resolved by 
electrophoresis in 2% agarose gel. The Pro allele was 279 bp, while 
the Arg allele was restricted into two fragments of 160 and 119 bp. 
Among the 145 colorectal cancer cases 49 cases (33.79%) were 
homozygous for the Arg72 allele (Arg/Arg), 18 cases (12.41%) were 
homozygous for the Pro72 allele (Pro/Pro) and 78 cases (53.8%) 
found in heterozygous (Arg/Pro).  
In conclusion, it can be said that p53Arg/Arg genotype may be 
correlated with possible increased risk of this kind of cancers in south 
west of Iran. 
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I. INTRODUCTION 
OLORECTAL cancer (CRC) also called colon cancer or 
large bowel cancer, includes cancerous growths in the 
colon, rectum and appendix [1]. It is the third most common 
cancer worldwide, the second leading cause of cancer death in 
the United States after lung cancer and the significant cause of 
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morbidity and mortality in western populations [2]. Colorectal 
cancer is a complex, multistep and multifactor process, and is 
thought to result from an interaction between environmental 
and genetic factors [3]. The risk of developing colorectal 
cancer is influenced by a number of factors, including sex, 
age, alcohol consumption, low-fiber or high-fat diet intake 
hereditary conditions, familial history of colorectal cancer, 
personal history of colonic polyps, bowel inflammatory 
diseases and a variety of genetic factors [3]. Among the 
genetic factors, the TP53 tumor suppressor gene is a suitable 
candidate for modulating colorectal cancer risk and is one of 
the most commonly mutated genes in all types of cancer 
(found in 50% of human cancers) [1], [4]. The p53 gene 
located on chromosome 17p13 [5]. It contains 11 exons and 
encodes for a 53 kDa multifunctional DNA-binding protein 
[6]. The p53 plays a critical role in the prevention of tumor 
formation; however, it is not required for normal cell growth. 
p53 can induce cell cycle arrest, DNA repair, differentiation, 
or apoptosis in response to oncogenic cellular stress including 
carcinogen induced DNA damage, abnormal proliferative 
stimulation [7]. In the cell, p53 protein binds DNA, which in 
turn stimulates another gene to produce a protein called p21 
that interacts with a cell division-stimulating protein (cdk2). 
When p21 is complexed with cdk2 the cell cannot pass 
through to the next stage of cell division. Mutant p53 can no 
longer bind DNA in an effective way, and as a consequence 
the p21 protein is not made available to act as the 'stop signal' 
for cell division. Thus cells divide uncontrollably, and form 
tumors [2]. p53 gene is the target of point mutations and of 
small deletions and insertions [8]. These mutations (mostly 
missense mutations) may damage the normal function of TP53 
as a transcription factor, and the induction of repair or 
apoptosis may be abolished. Consequently, other genetic 
alterations may accumulate in the cell [9]. 
To date, several polymorphisms in the wild-type p53 gene 
locus have been described [10]. At least three of them have 
been reported to be involved in cancer: the 16-bp duplication 
in intron 3, MspI restriction fragment length polymorphism 
(MspI-RFLP) in intron 6 (cc) and an arginine/praline variant 
at codon 72 in exon 4 [11], [12]. The most important p53 
polymorphism is the BstUI-RFLP in codon 72 of exon 4 
results in two alleles, the arginine (72Arg: CGC) and proline 
(72Pro: CCC) isoforms [3], [13]. This polymorphism has been 
reported to be associated with some tumor types [Pro: bladder 
cancer, lung cancer; Arg: hepatocellular carcinoma, cervical 
cancer, human papilloma virus (HPV)-associated cervical 
cancer]. An alteration of the p53 tumor suppressor gene is also 
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a mutational event involved in colorectal mucosa 
carcinogenesis [13], [4]. 
The Arg72Pro polymorphism is located in a praline rich 
region (residues 64-92) of the p53 protein, where the 72Pro 
amino acid constitutes one of five PXXP motifs resembling a 
SH3 binding domain. The region is required for the growth 
suppression and apoptosis mediated by p53 but not for cell 
cycle arrest [13], [9]. The p53Arg72 and p53Pro72 proteins 
do not differ in their ability to bind to DNA but they have 
some different biochemical and biological properties such as 
different binding to components of the transcriptional 
machinery and different activation of transcription [9], [14]. In 
this sense, it appears that this polymorphism may be 
associated with differential susceptibility to cancer [14]. The 
p53Arg72 protein induces apoptosis faster and suppresses 
transformation more efficiently than the p53Pro72 protein [7]. 
Conversely, the p53Arg72 protein is more susceptible to 
proteolysis mediated by the E6 protein of the human 
papillomavirus and degradation of p53 protein by HPV E6 is 
correlated with increased risk for HPV-associated cancers [7], 
[4]. Although the presence of HPV-DNA in colorectal tissues 
and adenocarcinomas was reported in populations from 
different regions, the association of p53 codon 72 
polymorphism with colorectal cancer taking into account HPV 
infection was investigated only once [15]. Therefore, we 
investigated the association of p53 codon 72 polymorphism 
with colon cancer cases in south west of Iran by Nested-PCR 
and RFLP analysis with BstUI restriction enzyme. 
 
II. MATERIALS AND METHODS 
 
Subjects 
A total of 145 patients (77 patients (53%) were male and 68 
(47%) were female) with colorectal cancer, who attended the 
clinical hospitals and clinical laboratories from south west of 
Iran were enrolled into this study. Their age ranged from 18–
85 years with a mean of 48.56 years (Table I). Informed 
consent was obtained from the patients and their blood 
samples were collected. Blood from 140 people who attended 
clinical laboratories and were negative for colorectal cancer 
served as normal control. 
 
DNA extraction from blood samples 
Genomic DNA was extracted from the blood samples by 
using a DNA extraction kit (QIAGEN Ltd., Crawley, UK) in 
accordance with the manufacturer’s protocol. The extracted 
DNA was stored at -20°C until further use. 
 
p53 codon 72 polymorphism analysis 
Nested-PCR and RFLP analyses were used to genotype the 







PREVALENCE OF CLORECTAL CANCER CASES ACCORDING TO 
RACIAL GROUPS 
 
Age group           Male               Female               Total                       
                         N           %          N          %          N         % 
30>                   4          2.77        5         3.44         9          6.2  
30-40                9          6.21        7         4.82        16        11.03 
40-50               16        11.05       13        8.95        29         20 
50-60               13         8.98        17        11.7        30        20.7 
60<                 35         24.19       26        17.89      61       42.07 
Total               77         53.2         68        46.8       145      100 
 
Gene amplification with Nested-PCR method 
The first PCR primers used were D1-F: 5′-GCT CTT TTC 
ACC CAT CTA CAG- 3′ and D2-R: 5′-TGA AGT CTC ATG 
GAA GCC AGC- 3′. PCR was performed in a final volume of 
25 µl reaction buffer containing 20 ng genomic DNA, 2 mM 
MgCl2, 25 pmole of each primer (D1-F and D2-R), 1 unit of 
Taq polymerase, 200 mM dNTP mix. Reaction mixtures were 
preincubated at 95°C for 5 minutes, followed by 30 cycles at 
94°C for 1 minute, 58°C for 1 minute, 72°C for 1 minute and 
a final extension step at 72°C for 5 minutes. Reaction mixture 
without DNA template was used as a negative control and that 
with known DNA template was used as a positive control 
which yielded PCR products of expected results. 
The second PCR primers used were F2-F: 5′-TCC CCC 
TTG CCG TCC CAA- 3′ and R2-R: 5′-CGT GCA AGT CAC 
AGA CTT- 3′. Reaction mixtures were as above, except that 
2.5µl of product from the first reaction as template DNA and 
the second primers set were used. 
 
RFLP analysis 
The amplified fragments from second PCR were purified 
and digested with BstUI restriction enzyme (Fermentas, 
Germany) according to the instructions of the manufacturer. 
Each digestion reaction mixture (30 µl) contained 10 units of 
BstUI endonucleas and 25 µl of second PCR products and was 
incubated at 37°C for 2 h.  After digestion, the fragments were 
electrophoresed on 2% agarose gel and visualized by UV light 
after ethidium bromide staining. 
 
Statistical analysis 
Analysis of data was performed using the SPSS version 
17.0 computer software (SPSS, Chicago, IL). Chi-square 
analysis was used to compare categorical variables. A 5% 
level of significance was used in the analysis and its 95% 
confidence interval (CI) was calculated to measure the 
association between P53 Arg72Pro polymorphism in case and 
control population. Whenever appropriate, the observed 
number of each genotype was compared with that expected 
for a population in the Hardy-Weinberg equilibrium by using 
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Amplified DNA fragments with Arg at codon 72 would 
contain the polymorphic BstUI site thus the Pro allele was 279 
bp, while the Arg allele was restricted into two fragments of 
160 and 119 bp. Among the 145 colorectal cancer cases 49 
cases (33.79%) were homozygous for the Arg72 allele 
(Arg/Arg), 18 cases (12.41%) were homozygous for the Pro72 
allele (Pro/Pro) and 78 cases (53.8%) found in heterozygous 
(Arg/Pro). The frequencies of the three P53 genotypes; 
Arg/Pro, Arg/Arge and Pro/Pro in controls were 60.7%, 20% 
and 19.3%, respectively. 
A representative Nested-PCR and RFLP pattern is depicted 
in Figure 1. The results on genotype distribution are presented 












Fig. 1 Gel electrophoresis of Nested-PCR product after 
digestion with BstUI. Lane M, 100 bp ladder; lanes 1 and 2 
are homozygote samples for Arg allele, lanes 3-5 are Arg/Pro 
heterozygote, and lanes 6 and 7 are  Pro homozygote samples. 
 
TABLE II 
DISTRIBUTION OF p53 CODON 72 POLYMORPHISM GENOTYPES 
AMONG COLORECTAL CANCER CASES AND CONTROLS IN SOUTH 
WEST OF IRAN 
Genotype  Cases (N=145)   Controls (N=140)   P-Value                         
                       N           %            N             %  
Arg/Arg        49          33.79        28           20          <0.01 
Arg/Pro        78          53.8          85           60.7       <0.02 
Pro/Pro        18          12.41        27           19.3       >0.005 
 
In this regard, an increase in the Arg/Arg genotype and a 
decrease in Pro/Pro genotype among patients was observed, 
and have a statistical significance (P<0.01). Comparison of the 
allele frequencies revealed an increase in the Arg allele among 
colorectal cancer patients compared to healthy individuals 
(Table III). However, the difference was not statistically 
significant (P=0.10). Comparison of the genotype frequencies 
between colorectal cancer patients and normal controls 
confirmed the accumulation of Arg/Arg genotype in these 










ALLELIC FREQUENCIES OF TP53 CODON 72 AMONG CLORECTAL 
CANCER CASES AND CONTROLS IN SOUTH WEST OF IRAN 
 
Alleles      Cases frequency   Controls frequency    P-Value 
                     N               %         N               % 
Arg              88            60.69      71            50.35      >0.10 
Pro               57            39.31     69             49.65      <0.05 
 
IV. DISCUSSION 
The p53 gene is one of the most extensively studied human 
genes because of its role as a tumor suppressor gene. The 
overall function of p53 is to maintain genomic integrity as a 
whole, providing a protective effect against tumorigenesis 
[13]. Recently, several studies have provided evidence that 
alterations of p53, either through genetic mutation or allelic 
polymorphisms, have been described as the most common 
genetic changes in human cancers, such as cervical cancer, 
breast cancer, lung and colorectal cancer [7], [13]. In Iran 
colorectal cancer accounts are approximately 8% of all 
malignancies [16].  The p53 gene is known to exhibit distinct 
mutational patterns in various cancer types. The 
proline/arginine substitution at codon 72 represents a 
common amino acid polymorphism in the p53 gene, the 
functional significance of which is unknown [13]. This may 
be due to the production of a mutant p53 protein that is not 
capable of inducing apoptosis in response to toxic 
environmental stimuli [7]. The role of the Arg/Pro 
polymorphism in colorectal cancer susceptibility has been 
examined in several studies, which have reported 
controversial results [17]. This controversy might be due to 
the fact that the genotype distribution of the p53 codon 72 
Arg/Pro polymorphism is varies in different geographic 
regions and ethnicity [16]. According to the literature, general 
populations from Latin America, United States and Europe 
exhibit high frequencies of the Arg allele compared to the Pro 
one, while lower prevalence's of Arg are found in African and 
Asian populations [18].  
Relevant to this, by nested-PCR, amplification of 4th exon 
were performed from isolated DNA samples of blood of colon 
cancer diagnosed in 145 cases and followed by enzyme 
restriction. As a result, the analysis of the p53 codon 72 
genotype revealed 49 cases (33.79%) arginine homozygotes 
(Arg/Arg), 18 cases (12.41%) proline homozygotes (Pro/Pro) 
and 78 cases (53.8%) arginine/proline heterozygotes 
(Arg/Pro). The frequencies of the three P53 genotypes; 
Arg/Pro, Arg/Arg and Pro/Pro in controls were 60.7%, 20% 
and 19.3%, respectively. In the present study, the frequency of 
p53 codon 72 genotypes among the controls and patients non- 
closely conformed to Hardy-Weinberg equilibrium and we 
found significant differences in the genotype or allele 
frequencies between the patients and the control groups. 
Moreover, the results showed increases in the Arg/Arg 
genotype and a decrease in Pro/Pro genotype among patients 
and an increase in the Arg allele.  
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In agreement with prior studies on breast, stomach and 
colorectal cancer in Iran we found significant differences in 
the genotype or allele frequencies between the patients and the 
control groups [16].  
A number of studies have failed to demonstrate the 
association between the p53 codon 72 polymorphism 
colorectal cancers. For example, Hamajima et al. analyzed this 
SNP in 147 colorectal cancer patients, and 241 non-cancer 
patients, in a Japanese population, and found no significant 
association between the genotype or allele frequencies and the 
diseases. However, other studies found the p53 codon 72 
polymorphism to be a genetic risk factor for colorectal cancer 
[12]. 
The genotype frequencies of TP53 codon 72 in 180 
sporadic colorectal adenocarcinomas and 180 healthy 
individuals from Isfahan province of Iran in 2008 was showed 
a significant difference between cases and controls for the 
Arg/Arg genotype compared with (grouped) Arg/Pro and 
Pro/Pro genotypes. The Arg allele was found more often in 
patients than in controls. The allele and genotype frequencies 
of the p53 codon 72 Arg/Pro polymorphism in stomach, 
colorectal adenocarcinoma and breast cancer patients and 
compared to the healthy individuals from the population of 
southern Iran showed non significant differences in the 
genotype or allele frequencies between the patients and the 
control groups [19]. Case and control studies conducted in 
Japan and Turkey failed to find an association between the 
prevalence of p53 polymorphism and colorectal cancer. In this 
study the allelic frequencies were concordant between the 
controls and colorectal cancer cases, reaching a frequency of 
approximately 0.6 for the Arg allele. 
In conclusion, the findings of the present study indicate that 
TP53 codon 72 polymorphism may be a genetic predisposing 
factor for colorectal adenocarcinomas and p53Arg72 protein 
may be correlated with possible increased risk of this kind of 
cancers in south west of Iran. 
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